• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume

expresspharmaJuly 01, 2020

Tag: COVID-19 , hydroxychloroquine , MHRA

A global trial designed to find out whether the anti-malaria drug hydroxychloroquine can prevent infection with COVID-19 is to restart after getting approval from the UK medicines agency.

The Medicines and Healthcare Products Regulatory Agency (MHRA) decision on the trial, which is known as the COPCOV trial, comes after the drug was found in another UK trial to have no benefit for patients already infected with COVID-19, the pandemic disease caused by the new coronavirus.


Previous:Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes

Next:Novartis' Global Innovative siRNA Long-Acting Lipid-lowering Therapy Submitted Clinical Application in China

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

UK regulator says COVID-19 prevention trial of hydroxychloroquine can resume | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
Hydroxychloroquine EP Impurity C

Hydroxychloroquine EP Impurity C
Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
99% up GMP,DMF Hydroxychloroquine sulfate CAS NO.747-36-4

99% up GMP,DMF Hydroxychloroquine sulfate CAS NO.747-36-4
Real Time Multiplex RT-PCR Kit (for COVID-19)

Real Time Multiplex RT-PCR Kit (for COVID-19)
Hydroxychloroquine Sulfate

Hydroxychloroquine Sulfate
Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
Hydroxychloroquine EP Impurity D

Hydroxychloroquine EP Impurity D
Hydroxychloroquine sulfate

Hydroxychloroquine sulfate
Hydroxychloroquine Sulfate

Hydroxychloroquine Sulfate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service